CT-based Biowave has developed a non-invasive medical device that electronically blocks pain in the body.
The Biowave device is based on a patent pending technology that generates a low frequency electric field in deep tissue, blocking the transmission of pain signals in the body.
Biowave devices are currently being used for investigational use in IRB approved clinical studies at major medical centres to treat chronic, acute and post-surgical pain in the low back, shoulder, neck, knee, elbow and other extremities.
Results from the company’s first clinical study at Weill Cornell Medical Center/New York Presbyterian Hospital, show that following a 20-minute treatment, benefits included an average 78% reduction in pain across all patient treatments and a dramatic increase in range of motion.
In addition, patients also had up to 24 hours of residual pain relief and increased mobility. The clinical results are significantly greater than any other non-invasive electrotherapy device currently in the marketplace.
Biowave has developed two devices, a professional model for use by physical therapists or physicians that treat patients in their office, and a cell phone sized ambulatory device for use by patients at home or work that will be available by prescription.
Biowave is currently in the midst of raising a $4 million Series C Preferred Equity round of financing to complete final production models of both its professional and wearable consumer devices, file for FDA approval and launch its products in the marketplace.